Navigation Links
FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
Date:3/11/2008

g-Plough announced that the FDA assigned priority review status to the company's New Drug Application (NDA) for sugammadex. In the U.S., priority review is granted to drugs that FDA believes will provide meaningful benefit over existing treatment options.

Sugammadex is specifically designed to reverse the effects of certain widely used muscle relaxants, marketed in the United States as ZEMURON(R) (rocuronium bromide) and vecuronium bromide. Muscle relaxants are used as part of general anesthesia during surgical procedures. Sugammadex works in an entirely novel way to encapsulate the muscle relaxant molecule and restore muscle function so that patients can breathe on their own again. Reversal with sugammadex is generally rapid and can even be used in emergency situations when immediate reversal of rocuronium is needed.

Schering-Plough acquired sugammadex through its combination with Organon BioSciences on November 19, 2007.

About Sugammadex

Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough Corporation. Sugammadex was designed to reverse the effects of rocuronium bromide (ZEMURON/ESMERON(R)/ESLAX(R)) or vecuronium bromide, muscle relaxants commonly used during surgeries that require profound muscle relaxation. Anesthesiologists use muscle relaxation to improve surgical conditions, to facilitate intubation and mechanical ventilation, and to reduce the chance of complications.

In clinical trials to date, sugammadex has demonstrated the ability to rapidly reverse shallow and profound depths of rocuronium-induced muscle relaxation, thereby enabling control of the onset and offset of skeletal muscle relaxation through the use of both drugs(1). Sugammadex also has demonstrated the ability to reverse the effects of muscle relaxation induced by vecuronium bromide. The most common adverse reactions (incidence >5%) seen with sugammadex in clinical trials were anesthetic compli
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
2. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
8. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
9. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
10. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
11. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Pharma Major Lupin Limited ... "Biocom" in Russia subject to certain ... pharmaceutical market which recorded RUB 765 billion in sales, placing ... the world in 2014 (IMS Health). For over a decade, ... continue with this trend, projecting Russia ...
(Date:7/2/2015)... CAMBRIDGE, Mass. , and DURHAM, N.C. ... Sciences , Inc. today announced its acquisition of assets ... Inc. (NYSE: PFE ) that had previously been ... Inc.  XRPro Sciences also acquired all of Pfizer,s rights ... re-launching the Icagen brand and will provide comprehensive services ...
(Date:7/2/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Emerging Technologies, Competitive Landscape" report to ... in Clinical Chemistry and Immunodiagnostics: Global Challenges, ... seven-country strategic analysis of major business opportunities ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, ... ended September 30, 2011. In the ... increased $1,567,764 to $2,783,240, up 129% compared to the ... strength in its prescription business.  Prescriptions filled increased from ...
... Nov. 17, 2011 Cohera Medical, a rapidly growing ... selling its lead product, TissuGlu® Surgical Adhesive, to hospitals ... regional launch will document and highlight the advantages of ... expansion throughout Germany and to additional European markets in ...
Cached Medicine Technology:HealthWarehouse.com Reports 129% Quarter-Over-Quarter Revenue Growth in the Third Quarter 2011 2Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany 2Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany 3
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national chief nursing officer recruitment ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:7/3/2015)... St. Louis, MO (PRWEB) , ... July 03, 2015 , ... ... new responsive website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just ... for talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer ...
(Date:7/3/2015)... ... ... Selfie on a Stick ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... smartphone has an incredibly powerful camera built into it. And when someone is traveling ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running a ... those of celebrities will have the opportunity to get 10% discount on orders that ... people do not have to use coupon codes or remember redemption codes. , ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... the Lone Star State. The premium frozen yogurt chain was listed as #22 on ... opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy 64, Suite ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... marital status can factor into the overall survival of ... most significant factor impacting overall survival, according to a ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the ... in 2008 approximately 215,020 new cases of lung cancer ...
... small tissue samples from patients with lung cancer and ... is now being utilized to better tailor the chemotherapy ... cell lung cancer, according to a study presented at ... by ASTRO, ASCO, IASLC and the University of Chicago., ...
... targeted therapies called monoclonal antibodies showed no safety ... non-small cell lung cancer according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ... and chemotherapy has been shown to increase the ...
... UPTON, NY A new study at the ... suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) ... associate methamphetamine with a particular environment. Specifically, animals ... in a location where they had previously been ...
... one milliard of a metre in size are widely ... There are also significant amounts of nanoparticles in exhaust ... health effects, because only a very small portion of ... safety risks. Nanoparticles have even been dubbed the asbestos ...
... Plans, Including Medicare Advantage & Managed Medicaid, Bring,The ... BRAUNFELS, Texas, Nov. 13 In a move,expanding ... today,announced agreements with 17 insurance companies that will ... obtain power mobility equipment,from The SCOOTER Store when ...
Cached Medicine News:Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Hope for treating relapse to methamphetamine abuse 2Health News:Hope for treating relapse to methamphetamine abuse 3Health News:Nanoparticles trigger cell death? 2Health News:The SCOOTER Store Expands Power Mobility Products, Services to 7 Million Health Plan Members 2
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: